Agios Pharmaceuticals Stock Forecast, Price & News

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Agios Pharmaceuticals stock.
View analyst ratings for Agios Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Agios Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Agios Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Agios Pharmaceuticals.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its quarterly earnings results on Wednesday, April, 28th. The biopharmaceutical company reported $26.95 earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.23) by $28.18. Agios Pharmaceuticals had a negative net margin of 161.11% and a negative trailing twelve-month return on equity of 40.48%.
View Agios Pharmaceuticals' earnings history.

Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AGIO shares have increased by 41.3% and is now trading at $57.74.
View which stocks have been most impacted by COVID-19.

12 brokers have issued 12-month price targets for Agios Pharmaceuticals' stock. Their forecasts range from $50.00 to $88.00. On average, they anticipate Agios Pharmaceuticals' stock price to reach $67.67 in the next year. This suggests a possible upside of 17.2% from the stock's current price.
View analysts' price targets for Agios Pharmaceuticals or view top-rated stocks among Wall Street analysts.

11 employees have rated Agios Pharmaceuticals CEO Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among Agios Pharmaceuticals' employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Agios Pharmaceuticals include Grifols (GRFS), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Maravai LifeSciences (MRVI), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Jazz Pharmaceuticals (JAZZ), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), Evotec (EVTCY), Ultragenyx Pharmaceutical (RARE) and Sarepta Therapeutics (SRPT).
View all of AGIO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), (CELG), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Agios Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.69%), Bellevue Group AG (6.49%), Price T Rowe Associates Inc. MD (4.81%), Rock Springs Capital Management LP (4.13%), Suvretta Capital Management LLC (1.76%) and Woodline Partners LP (1.34%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, Darrin Miles, David P Schenkein and Jacqualyn A Fouse.
View institutional ownership trends for Agios Pharmaceuticals.

AGIO stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Capital International Investors, D. E. Shaw & Co. Inc., Point72 Asset Management L.P., PDT Partners LLC, Alliancebernstein L.P., Credit Suisse AG, and Russell Investments Group Ltd.. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, and Darrin Miles.
View insider buying and selling activity for Agios Pharmaceuticals or view top insider-selling stocks.

AGIO stock was purchased by a variety of institutional investors in the last quarter, including Suvretta Capital Management LLC, Woodline Partners LP, Bellevue Group AG, Eagle Health Investments LP, BlackRock Inc., Morgan Stanley, Citigroup Inc., and HRT Financial LP. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, and Jacqualyn A Fouse.
View insider buying and selling activity for Agios Pharmaceuticals or or view top insider-buying stocks.

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGIO stock can currently be purchased for approximately $57.74.

Agios Pharmaceuticals has a market capitalization of $3.56 billion and generates $203.20 million in revenue each year. The biopharmaceutical company earns $-327,370,000.00 in net income (profit) each year or ($4.74) on an earnings per share basis.

Agios Pharmaceuticals employs 562 workers across the globe.

The official website for Agios Pharmaceuticals is www.agios.com.

Agios Pharmaceuticals is headquartered at 88 SIDNEY STREET, CAMBRIDGE MA, 02139.

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]